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IV: Intravenous
IS: Immunosuppressants
KS: Kaposi’s sarcoma
NS: Not specifiedINTRODUCTION
Kaposi’s sarcoma (KS) is a lymphoangioprolifer-
ative neoplasm induced by human herpes virus 8
(HHV-8). Four clinical variants have been recog-
nized: classical, African endemic, AIDS-related, and
KS caused by iatrogenic immunosuppression. The
latter is typically associated with the use of immu-
nosuppressive therapy in organ transplant recipi-
ents; however, iatrogenic KS can also occur in
patients receiving immunosuppression for other in-
dications, such as autoimmune disorders.1
Granulomatosis with polyangiitis (GPA), formally
known as Wegener’s granulomatosis, is a multi-
system necrotizing autoimmune vasculitis, which
can be fatal and is classically treated with cyclophos-
phamide (CP) and prednisone.2 To our knowledge,
only 3 cases report the development of iatrogenic KS
in the context of GPA.3-5 We describe a case of an
HIV-negative patient who had iatrogenic KS after
GPA therapy, did not improve after first-line treat-
ment reduction or withdrawal of immunosuppres-
sion, and consequently required systemic treatment
with liposomal doxorubicin.CASE REPORT
A previously healthy 66-year-old Romanian
woman had GPA diagnosed in 2012. Her treatment
regimen consisted of high-dose intravenous (IV)
cyclophosphamide (800 mg/mo) and systemic cor-
ticosteroids (IV methylprednisolone pulse followed
by 25 mg of oral prednisone daily). After 5 months of
therapy, several painless, red-to-violaceous coa-
lescing papules appeared on her right arm, shoulder,the Department of Medicine, Division of Dermatology,
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was achieved, and cyclophosphamide was changed
to azathioprine (2 mg/kg/d) for maintenance,
whereas prednisone was slowly tapered over 12
months to 10 mg/d. Despite reduced immunosup-
pression during the maintenance phase, the patient’s
lesions progressed, and the dermatology service was
consulted. At the time of initial presentation to our
clinic, skin lesions involved all 4 limbs and trunk (Fig
1, A). Skin biopsy confirmed plaque-stage KS (Fig 1,
B) and imaging and endoscopy ruled out systemic
involvement. Diagnosis of cutaneous iatrogenic KS
was made, and considering the clinical remission of
GPA, azathioprine was stopped and prednisone was
further tapered to 8 mg/d. Two months later, despite
continued reduction of immunosuppression, her KS
lesions became more symptomatic with worsening
pain, edema, and paresthesias. Further clinical dete-
rioration, prompted systemic treatment with IV
doxorubicin (36 mg every 3 weeks for 6 doses
followed by 36 mg every 4 weeks for 2 doses and
now receiving 36 mg every 8 weeks as needed). KS
lesions improved after the first treatment (Fig 2), and
remission was achieved on treatment completion.JAAD Case Reports 2015;1:71-3.
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Fig 1. A, KS lesions before treatment with doxorubicin. B, Left leg biopsy shows proliferation
of endothelial spindle cells forming vascular spaces indicating KS plaque stage (Hematoxylin-
eosin stain). Positive HHV-8 nuclear staining was detected in spindle and endothelial cells
(Inset).
Fig 2. Clinical appearance of KS lesions after 1 year of
treatment with doxorubicin.
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DISCUSSION
Patients originating from Eastern Europe and the
Mediterranean belt, where exposure to HHV-8 is
endemic in some regions, are at an increased risk
of KS in the context of immune suppression.1
Decreased immunity leads to the reactivation of
HHV-8, a virus that exerts its oncogenic effects by
inhibiting 2 major tumor suppressor proteins in
endothelial cells; the retinoblastoma protein and
p53.1 Maintaining immunosuppression leads to
further progression of iatrogenic KS. However,
restoring immune defenses by reducing or with-
drawing immunosuppression may induce sponta-
neous KS remission and represents the first-line
therapy for iatrogenic KS.1 Iatrogenic KS can present
a therapeutic dilemma, as decreasing the level ofimmunosuppression may not be possible or may
come at the high cost of organ rejection, such as in
the case of organ transplant recipients or organ
damage in the case of patients with autoimmune
disorders.
Most patients with untreated generalized
GPA experience a rapidly progressive fatal illness.
Before the advent of immunosuppressive therapy,
the 5-month survival rate for GPA was only 18%.2
Currently, with the use of systemic steroids and
cyclophosphamide in conjunction with 18 months
of maintenance therapy with less-toxic agents, GPA
remission can be achieved in more than 75% of
cases.2 Only 3 cases of iatrogenic KS have been
reported in patients with GPA (Table I). Two patients
improved after reduction or withdrawal of immuno-
suppressant drugs. Immunosuppression could
not be reversed for the third patient because of
underlying disease, which eventually led to
patient death. Of note, the first 2 patients improved
with prednisone taper despite continuation of
cyclophosphamide.
KS was also reported in patients receiving
corticosteroids for other indications, including pain
from ulnar nerve entrapment and autoimmune
thrombocytopenia.6,7 In these cases, regression of
KS lesions were noted within 3 to 4 months after
reduction or discontinuation of immunosuppres-
sion.6,7 In-vitro studies suggest corticosteroids
induce KS by indirectly inhibiting transforming
growth factor beta, a protein that inhibits growth
of endothelial cells.8 In our patient, despite pred-
nisone taper over 14 months and discontinuation of
Table I. Outcome of iatrogenic KS in patients receiving immunosuppressive therapy for GPA
Year Age Sex Ethnicity
IS before KS
development
IS at time of KS
improvement
Time to regression of
KS after reducing IS
Deschenes et al3 2003 54 M Caucasian CP 150 mg/d
Pred 80 mg/d
CP 50 mg/d
Pred 10 mg/d
4 mo
Erban and Sokas4 1988 78 M Polish CP 100 mg/d
Pred 60 mg/d
CP 75 mg/d 1 wk
Hoff and Rodevand5 2005 74 M NS CP cumulative dose
200,000 mg
AZA, NS
Pred, NS
MTX 15 mg/wk
Not applicable NS
AZA, Azathioprine; CP, Cyclophosphamide; GPA, Granulomatosis with polyangiitis; IS, Immunosuppressants; KS, Kaposi’s sarcoma; M, male;
MTX, Methotrexate; NS, Not specified; Pred, Prednisone.
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alternative treatment.
Previous case reports and small case series
reported promising results using liposomal
doxorubicin, etoposide, and taxanes in the treat-
ment of iatrogenic KS.9 Liposomal doxorubicin is
more effective and less neurotoxic than other
chemotherapeutic agents because of its ability to
extravasate through leaky vessels of angiogenic
tumors, making it an ideal drug in the treatment
of KS.9 Moreover, the addition of polyethylene
glycol to the liposomal component of doxorubicin
alters the drug’s kinetics resulting in a prolonged
half-life, greater accumulation in KS tissues, and,
consequently, enhanced tumoral toxicity.10 It was
proposed that doxorubicin may decrease HHV-8
viremia and lead to regression of KS by suppress-
ing cytokine production from infected cells and
by inhibiting HHV-8 replication in peripheral
blood monocytes.10
This case highlights the therapeutic challenge
of iatrogenic KS, as reduction or removal of
immunosuppression may not always lead to
resolution of KS. In these cases or in cases
in which reduction of immunosuppression
may not be possible, systemic therapy with
agents such as liposomal doxorubicin should be
considered.REFERENCES
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